Pharmaceutical intermediates
Risdiplam Intermediates
3 pharmaceutical intermediates for Risdiplam. Indication: Spinal Muscular Atrophy (SMA).
About Risdiplam
- Originator
- Ptc Therapeutics Inc
- Indication
- Spinal Muscular Atrophy (SMA)
- Approved Date
- 08/07/2020
- NCE Patent
- 08/07/2025
- DS/DP
- 02/08/2033
Available intermediates
3 intermediates currently listed for Risdiplam. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 7-fluoro-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one | 1449598-85-9 | / | / |
| 4-Boc-4,7-diazaspiro[2.5]octane | 674792-08-6 | / | / |
| 2,8-Dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine | 1825352-86-0 | / | / |
Other programs under R
Building toward Risdiplam?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →